Surgical robots, early cancer tests top CB Insights digital health startup list

The most promising, as aggregated in annual rankings from the firm, have raised over $20 billion in total funding for more than 600 deals with 900-plus investors.

By Hailey Mensik , Maria Rachal • Aug. 14, 2020

Myriad names new CEO, reports sales sank 57% amid COVID-19 shutdowns

The beleaguered molecular diagnostic company had competitive weaknesses prior to the pandemic that remain unresolved. But SVB Leerink analysts contend Paul Diaz’s appointment could help it "turn the corner."

By Nick Paul Taylor • Aug. 14, 2020

Explore the Trendline➔

Top 5 stories from MedTech Dive

From haphazard layoffs at the Food and Drug Administration to the industry’s current IPO environment and tracking FDA-authorized AI devices, here is a collection of top stories from MedTech Dive.

By MedTech Dive staff

Thermo Fisher-Qiagen deal falls apart after failing to secure shareholder support

Thermo Fisher recently raised its bid for Qiagen shares, taking into account the company's COVID-19 testing gains. But when the offer expired Monday, less than half of shares were tendered.

By Nick Paul Taylor , Maria Rachal , Greg Slabodkin • Updated Aug. 13, 2020

Hologic jumps into COVID-19 pool testing, aimed at boosting lab capacity

LabCorp and Quest last month announced their own specimen pooling methods. Unlike Hologic, however, they have already been granted emergency use authorizations by FDA. 

By Nick Paul Taylor • Aug. 12, 2020

State coronavirus testing targets diverge, some plan declines by December

Monthly testing goals submitted to HHS show Connecticut and Illinois are among those looking to multiply monthly testing volumes, while Louisiana and Maine, for example, are projecting lower levels at the end of the year.

By Maria Rachal • Aug. 11, 2020

Guardant companion diagnostic gets FDA nod as 1st liquid biopsy with NGS

Cowen analysts noted Guardant360 will be reimbursed under an existing Medicare national coverage determination for genetic profiling using next-generation sequencing, predicting initial reimbursement at around $3,500.  

By Susan Kelly • Aug. 10, 2020

Notified bodies list for incoming EU regs hits 20 with designation of DQS for MDR

The 16 notified bodies now allowed to complete work under the Medical Device Regulation and the four OK'd under its In Vitro Diagnostic counterpart together meet the goal that authorities had hoped to achieve by the start of 2020.

By Nick Paul Taylor • Aug. 10, 2020

Healthcare gains jobs in July, but still down 800K from February

The latest report shows ambulatory, outpatient, and medical and diagnostic lab service jobs are creeping closer to last year's levels.

By Hailey Mensik • Aug. 7, 2020

Guardant growth slows in Q2 but still beats expectations

The precision oncology company reported a 23% increase in sales, yet refrained from reinstating full-year guidance amid ongoing uncertainty about the impact of COVID-19. 

By Nick Paul Taylor • Aug. 7, 2020

BD sales slide below expectations, as COVID-19 antigen test gains momentum

In the month since the launch of its antigen test, CEO Tom Polen said BD shipped more Veritor readers than in a typical year. Still, the medtech's stock fell 9% Thursday amid pressure on other business lines.

By Greg Slabodkin • Aug. 6, 2020

10 states now on board to buy Quidel, BD antigen tests

With the latest additions of Arkansas and Rhode Island, there are now five Democratic and five Republican governors each planning to acquire half a million of the rapid point-of-care diagnostics from the medtechs.

By Greg Slabodkin • Updated Aug. 19, 2020

Americas drag on Qiagen as Thermo Fisher deal goes down to the wire

A hedge fund that owns 8% of Qiagen "fully" expects the Thermo Fisher offer to fail, calling it “wholly inadequate.”

By Nick Paul Taylor • Aug. 5, 2020

CMS proposes eliminating inpatient-only list, in potential boon for ASCs

The agency would begin by removing about 300 musculoskeletal-related services, which could further accelerate ambulatory surgery centers' important role as medtech customers.

By Shannon Muchmore • Aug. 4, 2020

Device maker Q2 reports show optimism on COVID-19 recovery, but flare-ups keep guidance at bay

Since March and April lows, business volume has improved sequentially. Still, many medtechs are tightlipped on what that may mean for financial performance for the rest of the year.

By Maria Rachal • Aug. 3, 2020

Quidel says COVID-19 antigen test buoys 270% rise in rapid diagnostics unit, demand 'more than we can satisfy'

The company late Thursday reported second quarter total sales of $201.8 million, an 86% increase over the prior year, with strong demand for its PCR and antigen tests for the coronavirus.

By Greg Slabodkin • Updated July 31, 2020

Exact Sciences bets pandemic will accelerate adoption of Cologuard

The cancer diagnostics company is spending to drive a lasting move from colonoscopies to its at-home screening test, including running a $70 million TV advertising campaign.

By Nick Paul Taylor • July 31, 2020

Hologic blows away earnings expectations on COVID-19 testing surge

The manufacturer said it has ramped production capacity to at least 1.5 million coronavirus tests a week, estimating it provided a quarter to a third of the test results delivered in the U.S. during the recent quarter.

By Susan Kelly • July 30, 2020

Coronavirus could fuel clinical lab M&A by stressing smaller hospital players

Consultancy Kaufman Hall predicts a ramp-up of deals throughout the year, as hospital-owned labs seek support amid the pandemic. That forecast meshes with comments from Quest's CEO last week.

By Nick Paul Taylor • July 29, 2020

Hologic wins HHS-DOD contract to boost COVID-19 test supplies production

Some analysts peg Hologic's current share of the U.S. COVID-19 molecular testing market between 25% and 30% and predict the manufacturing expansion could create a $150 million windfall in quarterly revenue.  

By Susan Kelly • July 28, 2020

LabCorp says COVID-19 testing 'more than' offsets still-recovering base business

LabCorp's improving average turnaround time for reporting molecular diagnostic test results stands in contrast to Quest, which for most of July has reported average result wait times for non-priority patients of a week or more.

By Greg Slabodkin • July 28, 2020

Color targets supply, staffing bottlenecks with updated coronavirus test EUA

The population health technology company's test uses dry nasal swabs, eliminating the need for the viral transport media that's been in short supply and limited scaling by lab giants Quest and LabCorp.

By Nick Paul Taylor • July 28, 2020

Coronavirus testing hits a wall: Where do we go from here?

As LabCorp and Quest are backlogged in delivering molecular test results, some public health officials are calling for a shift in testing approach from slow and accurate to fast and good enough to meet demand.

By Greg Slabodkin • July 27, 2020

Medtech and COVID-19: 6 months into the public health emergency

MedTech Dive examines where the industry stands with testing and the future of those emergency use-authorized diagnostics, as well as how it's adapting to a rebound in elective surgeries and various supply chain challenges.

July 27, 2020

How COVID-19 is challenging and changing medtech supply chain management

Four experts share insights on the supply and demand hangups medtechs have been working through during the pandemic, and a few early takeaways the industry can carry forward.

By Maria Rachal • July 27, 2020

Diagnostics makers must plan for EUA products to have post-pandemic future

An extension to the public health emergency formalized a reprieve for emergency use authorizations, but manufacturers should act now if they want products to stay on the market when the crisis ends, compliance experts say.

By Greg Slabodkin • July 27, 2020